CBDV

Cannabidivarin

C₁₉H₂₆O₂ 286.42 g/mol Non-intoxicating

Typical abundancetrace

Receptor targets

TRP channels (TRPA1 · TRPV1 · TRPM8) · low CB1/CB2 affinity

Mechanism of action

Propyl analogue of CBD. Acts largely through transient receptor potential (TRP) channels rather than the cannabinoid receptors, and shows anticonvulsant activity in preclinical seizure models.

Reported effects

Anticonvulsant (preclinical)Anti-nausea (preclinical)

Common terpenes

Myrcene Caryophyllene Linalool

Research

Clinically investigated as GW Pharmaceuticals' GWP42006; a Phase 2a trial in adult focal epilepsy did not separate from placebo, and development continued in autism spectrum disorder and Rett syndrome.